Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: KanadaFázis nélkül

MYocarditis and/or Pericarditis Following mRNA COVID-19 VACCination National Surveillance Study

A legfontosabb adatok

Ki végzi
Cardiology Research UBC
Hol
Vancouver (Kanada)A helyszín megnézése
Azonosító
Állapot
Toboroz
Résztvevők
500 fő, tervezett
Kezdés
2023. ápr. 23.
Várható befejezés
2027. ápr. 23.
A vizsgálat típusa
Megfigyeléses, 5 csoport
A vizsgált kezelések
  • Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire
  • Baseline Quality of Life questionnaire
A regiszteradat frissítve
2026. november 3.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for people with inflammation of the heart muscle (myocarditis) or of the lining around the heart (pericarditis). This includes cases after an mRNA COVID-19 vaccine, after COVID-19 infection, or from other causes.

Nem
All sexes can join.
A betegség stádiuma
Myocarditis or pericarditis that meets Brighton Criteria levels 1-3. For the vaccine or COVID-19 groups, it started within 42 days of vaccination or infection.
Korábbi kezelés
For the vaccine group: a COVID-19 vaccination within the previous 42 days.
Biomarker vagy leletérték
At least one objective finding, such as raised Troponin T, Troponin I or CK-MB, raised ESR, CRP, hs-CRP or D-Dimer, or abnormal heart scans or ECG.

A részvétel fő kizáró okai

  • Cases at Brighton Criteria level 4 (not enough evidence for myocarditis) or level 5 (not myocarditis).
  • Another diagnosis explains the symptoms, such as a heart attack (myocardial infarction).
  • For the vaccine or COVID-19 groups: another cause such as infectious or autoimmune myocarditis.
  • For the follow-up part: no consent given by the patient or by an authorised substitute decision maker.

A regiszter feltételei, szó szerint

Mind a 6 feltétel megnézéseKevesebb

Ki vehet részt

  • Inclusion criteria for vaccine associated myocarditis/pericarditis; COVID-19 vaccination within previous 42 days. AND; At least one cardiac symptom of suspected myocarditis/pericarditis (Appendix 5); OR At least two non-specific symptoms (Appendix 5). OR In infants and young children, at least two non-specific pediatric symptoms (Appendix 5); OR No symptoms, but abnormal histopathology or a combination of abnormal cardiac biomarkers with abnormal cardiac imaging (echo or MRI); AND; At least one of the following objective findings (Brighton Criteria case definitions, Appendices 1 to 5):; Histopathologic examination of myocardial tissue (autopsy or endomyocardial biopsy) showed myocardial inflammation; Elevated myocardial biomarker (Troponin T, Troponin I, or CK-MB); Cardiac MRI abnormality; Echocardiographic abnormality; New or worsening arrhythmia on electrocardiogram, Holter monitor, or telemetry; Elevated inflammation biomarkers: erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), hs-CRP, or D-Dimer; Physical examination pericardial friction rub or pulsus paradoxus; Pericardial fluid or inflammation by imaging (echo, MRI, or CT); Enlarged heart on chest radiograph; AND; No alternative cause of presentation. e.g. infectious or autoimmune myocarditis
  • Inclusion criteria for COVID-19 associated myocarditis/pericarditis; COVID-19 infection within the previous 42 days; AND; Myocarditis/pericarditis as per Brighton Criteria for vaccine associated myocarditis/pericarditis; AND; No alternative cause of presentation
  • Myocarditis/pericarditis as per Brighton Criteria for vaccine associated myocarditis/pericarditis; AND
  • No alternative cause of presentation

Ki nem vehet részt

  • Patients not fulfilling Brighton Criteria levels 1-3 will be excluded if they are level 4 (insufficient evidence for myocarditis) or Level 5 (not myocarditis) or have an alternative diagnosis such as myocardial infarction
  • For prospective invitation and follow-up, inability to provide informed consent. Consent will be sought from patients or their authorised substitute decision maker

Helyszínek itt: Kanada

  • Vancouver General HospitalVancouver, KanadaContact: Jenny Petterson, MScRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

Myocarditis is inflammation of the heart muscle. Pericarditis is inflammation of the lining surrounding the heart muscle. Symptoms of these conditions can include pain in the chest and rapid or irregular heartbeat. There are many different causes for myocarditis and pericarditis including COVID-19 infection.

A teljes eredeti leírásKevesebb

The MYCOVACC study will identify patients using local screening strategies, including research communications, care provider referrals, and medical record review. The retrospective component of the study will collect information about patients suffering from vaccine associated myopericarditis and COVID-19 associated myopericarditis. Consenting patients will then be prospectively followed according to standard of care protocols. The main objectives of MYCOVACC are to describe the rate of major adverse cardiovascular events, functional outcomes including quality of life, and myocardial recovery through imaging.

A vizsgálat 5 csoportja

  • mRNA COVID-19 vaccine associated myocarditis

    Participants who had developed myocarditis within 42 days of getting a mRNA COVID-19 vaccine

    Kezelés: Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire

  • mRNA COVID-19 vaccine associated pericarditis

    Participants who had developed pericarditis within 42 days of getting a mRNA COVID-19 vaccine

    Kezelés: Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire

  • COVID-19 infection associated myocarditis

    Participants who had developed myocarditis within 42 days of being infected with the SARS-COV-2 virus

    Kezelés: Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire

  • COVID-19 infection associated pericarditis

    Participants who had developed pericarditis within 42 days of being infected with the SARS-COV-2 virus

    Kezelés: Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire

  • Alternative etiology myocarditis

    Any participants with myocarditis that is not associated with the mRNA COVID-19 vaccine or SARS-COV-2 viral infection

    Kezelés: Baseline Quality of Life questionnaire

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2026. november 3.